Results 121 to 130 of about 16,388 (147)

Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial. [PDF]

J Am Heart Assoc
Knowlton KU, Navar AM, Anderson JL, Brown AS, Muhlestein JB, Kleeman K, Sarwat S, Abbas CA, Ramirez MA, Grines CL, Abo-Auda WS, Desai NR.   +11 more
europepmc   +1 more source

Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy. [PDF]

Eur Heart J Qual Care Clin Outcomes
Engebretsen I, Ødegaard KM, Halvorsen S, Bugge C, Kristiansen IS, Støvring H, Munkhaugen J.   +6 more
europepmc   +1 more source

Differential expression of POMC-processing genes in corticotroph tumors. [PDF]

Endocr Oncol
Lamback E, Miranda RL, Mendonça L, de Figueiredo CS, Salum KCR, Dezonne RS, Wildemberg LE, Gadelha MR.   +7 more
europepmc   +1 more source

Obecetrapib, CETP inhibition, and atherosclerosis: there is light at the end of the tunnel. [PDF]

J Lipid Res
Toth PP, Banach M.
europepmc   +1 more source

High levels of serum cholesterol increase the risk of developing vessel co-opting tumors in colorectal cancer liver metastases. [PDF]

FEBS J
Gantz A, Kapelanski-Lamoureux A, Rada M, Krzywon L, Tsamchoe M, Tsatoumas A, Petrillo SK, Seidah NG, Lazaris A, Metrakos P.   +9 more
europepmc   +1 more source

Ezetimibe vs Inclisiran in Coronary Artery Disease and Hyperlipidemia: A Propensity-Matched Analysis. [PDF]

JACC Adv
Akbar UA, Ijaz H, Banga A, Cheshire M, Shakeel S, Jena N, Alexander T, Dani SS.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mouse Models of Human Proprotein Convertase Insufficiency

Endocrine Reviews, 2021
Iris Lindberg, Lindberg Iris
exaly  

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Stroke, 2020
Robert P Giugliano, Terje R Pedersen, Jeffrey L Saver   +2 more
exaly  

Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9

European Heart Journal, 2020
Hyun-Duk Jang, Hwan Lee, Seung Ji Lee
exaly